A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Motor Neuron Disease
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2018
At a glance
- Drugs FLX 787 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Acronyms COMMEND
- Sponsors Flex Pharma
- 18 Jun 2018 Status changed from active, no longer recruiting to discontinued, because company is ending its ongoing Phase 2 clinical trial investigations of FLX-787 due to oral tolerability concerns observed in a subset of patients being treated for Charcot-Marie-Tooth disease, with the oral disintegrating tablet formulation at 30 mg, taken three times a day, according to a Flex Pharma media release.
- 13 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Mar 2018 According to a Flex Pharma media release, company expects to report topline results from this study in early 2019.